AR117251A1 - Compuesto macrocíclico como activador de nrf2 - Google Patents
Compuesto macrocíclico como activador de nrf2Info
- Publication number
- AR117251A1 AR117251A1 ARP190103549A ARP190103549A AR117251A1 AR 117251 A1 AR117251 A1 AR 117251A1 AR P190103549 A ARP190103549 A AR P190103549A AR P190103549 A ARP190103549 A AR P190103549A AR 117251 A1 AR117251 A1 AR 117251A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- ring
- nrf2
- alkyl group
- hydrogen atom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos macrocíclicos como activadores de NRF2, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades mediadas por la activación de NRF2. Reivindicación 1: Un compuesto caracterizado porque es representado por la fórmula (1), donde R¹ es OH, ORʸ o NHRʸ; Rʸ es un grupo C₁₋₆ alquilo opcionalmente sustituido o un grupo cíclico opcionalmente sustituido; R² y R³, que pueden ser iguales o diferentes, son un átomo de hidrógeno o un grupo C₁₋₆ alquilo opcionalmente sustituido, o R² y R³ se unen para formar un grupo C₃₋₆ cicloalquilo; X es C(=O), SO₂ o CRˣ¹Rˣ²; Rˣ¹ y Rˣ², que pueden ser iguales o diferentes, son un átomo de hidrógeno o un grupo C₁₋₆ alquilo opcionalmente sustituido; el anillo A es un anillo benceno que puede tener uno o más sustituyentes adicionales; el anillo B es un anillo benceno que puede tener uno o más sustituyentes adicionales; el anillo C es un anillo aromático de 5 ó 6 miembros opcionalmente sustituido que puede contener uno o más heteroátomos; y L es C₄₋₈ alquileno lineal, saturado o insaturado, opcionalmente sustituido opcionalmente insertado por un heteroátomo; o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018228234 | 2018-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117251A1 true AR117251A1 (es) | 2021-07-21 |
Family
ID=70975488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103549A AR117251A1 (es) | 2018-12-05 | 2019-12-04 | Compuesto macrocíclico como activador de nrf2 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11518763B2 (es) |
| EP (1) | EP3890738A4 (es) |
| JP (1) | JP2022510736A (es) |
| KR (1) | KR20210099622A (es) |
| CN (1) | CN113164468A (es) |
| AR (1) | AR117251A1 (es) |
| AU (1) | AU2019391942B2 (es) |
| BR (1) | BR112021010704A2 (es) |
| CA (1) | CA3121952A1 (es) |
| CL (1) | CL2021001451A1 (es) |
| CO (1) | CO2021007304A2 (es) |
| MX (1) | MX2021006527A (es) |
| PH (1) | PH12021551262A1 (es) |
| SG (1) | SG11202105125XA (es) |
| TW (1) | TWI820266B (es) |
| UA (1) | UA127872C2 (es) |
| WO (1) | WO2020116660A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4364804A2 (en) | 2018-08-20 | 2024-05-08 | Janssen Pharmaceutica NV | Inhibitors of keap1-nrf2 protein-protein interaction |
| KR20230104126A (ko) * | 2020-09-14 | 2023-07-07 | 사노피 | 적혈구 질환 및 염증성 질병의 치료를 위한 테트라하이드로이소퀴놀린 유도체 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029393T2 (en) | 2010-08-31 | 2017-03-28 | Bionure Farma S L | Neurotrophin receptor agonists and their use as medicaments |
| CN105339358B (zh) | 2013-06-21 | 2019-06-04 | 卡尔约药物治疗公司 | 核转运调节剂及其用途 |
| EP3083614B1 (en) * | 2013-12-18 | 2020-01-15 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| MA52309A (fr) | 2015-06-15 | 2021-02-24 | Astex Therapeutics Ltd | Régulateurs de nrf2 |
| CA2988373A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| EP3766878B1 (en) | 2015-06-15 | 2022-03-16 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| US10201531B2 (en) | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| US20200071310A1 (en) | 2016-12-12 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| JP2020500919A (ja) | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしての３−カルボン酸ピロール |
| WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
| US20220002272A1 (en) | 2016-12-14 | 2022-01-06 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl lactams as nrf2 activators |
| EP3555078B1 (en) | 2016-12-14 | 2024-03-27 | GlaxoSmithKline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 activators |
| RU2019121673A (ru) | 2016-12-15 | 2021-01-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Активаторы nrf2 |
| WO2018109649A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as nrf2 regulators |
| AR110590A1 (es) | 2016-12-27 | 2019-04-10 | Biogen Ma Inc | Activador de nrf2 |
| US20190389836A1 (en) | 2017-01-30 | 2019-12-26 | Biogen Ma Inc. | Nrf2 activator |
| WO2018140738A1 (en) | 2017-01-30 | 2018-08-02 | Biogen Ma Inc. | Nrf 2 activator |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
-
2019
- 2019-12-04 AU AU2019391942A patent/AU2019391942B2/en active Active
- 2019-12-04 CN CN201980080214.5A patent/CN113164468A/zh active Pending
- 2019-12-04 SG SG11202105125XA patent/SG11202105125XA/en unknown
- 2019-12-04 BR BR112021010704-5A patent/BR112021010704A2/pt unknown
- 2019-12-04 JP JP2021554804A patent/JP2022510736A/ja active Pending
- 2019-12-04 TW TW108144324A patent/TWI820266B/zh active
- 2019-12-04 WO PCT/JP2019/048593 patent/WO2020116660A1/en unknown
- 2019-12-04 EP EP19892751.9A patent/EP3890738A4/en active Pending
- 2019-12-04 US US17/299,659 patent/US11518763B2/en active Active
- 2019-12-04 MX MX2021006527A patent/MX2021006527A/es unknown
- 2019-12-04 KR KR1020217020790A patent/KR20210099622A/ko active Search and Examination
- 2019-12-04 AR ARP190103549A patent/AR117251A1/es unknown
- 2019-12-04 CA CA3121952A patent/CA3121952A1/en active Pending
- 2019-12-04 UA UAA202102856A patent/UA127872C2/uk unknown
-
2021
- 2021-05-31 PH PH12021551262A patent/PH12021551262A1/en unknown
- 2021-06-02 CL CL2021001451A patent/CL2021001451A1/es unknown
- 2021-06-03 CO CONC2021/0007304A patent/CO2021007304A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022510736A (ja) | 2022-01-27 |
| US11518763B2 (en) | 2022-12-06 |
| BR112021010704A2 (pt) | 2021-08-24 |
| MX2021006527A (es) | 2021-07-21 |
| UA127872C2 (uk) | 2024-01-31 |
| EP3890738A4 (en) | 2022-08-17 |
| AU2019391942A1 (en) | 2021-06-03 |
| CL2021001451A1 (es) | 2021-12-24 |
| TW202039494A (zh) | 2020-11-01 |
| AU2019391942B2 (en) | 2024-03-21 |
| KR20210099622A (ko) | 2021-08-12 |
| SG11202105125XA (en) | 2021-06-29 |
| PH12021551262A1 (en) | 2021-10-25 |
| CA3121952A1 (en) | 2020-06-11 |
| US20220119391A1 (en) | 2022-04-21 |
| CO2021007304A2 (es) | 2021-06-21 |
| WO2020116660A1 (en) | 2020-06-11 |
| EP3890738A1 (en) | 2021-10-13 |
| TWI820266B (zh) | 2023-11-01 |
| CN113164468A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120700A1 (es) | Inhibidores de kras g12c | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| ECSP17002135A (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
| CR20150412A (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| UY38428A (es) | Nuevos compuestos antihelmínticos | |
| PE20190968A1 (es) | Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih | |
| AR107738A1 (es) | Amidas de ácido n-(5-halógen-1,3,4-oxadiazol-2-il)arilcarboxílico y su uso como herbicidas | |
| CU20160148A7 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2 | |
| AR113958A1 (es) | Macrociclos a como inhibidores de pde1 | |
| CO2017008809A2 (es) | Compuestos de benzoxaborol y uso de los mismos | |
| AR117251A1 (es) | Compuesto macrocíclico como activador de nrf2 | |
| EA201691760A1 (ru) | Тритерпеноиды с активностью ингибиторов созревания вич, замещенные в положении 3 неароматическим кольцом, имеющим галогеналкильный заместитель | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| NI201800063A (es) | Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| AR095059A1 (es) | Compuestos herbicidas | |
| CO2020006257A2 (es) | Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| UY37641A (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
| AR116877A1 (es) | 3-amino-piridazinas como inhibidores de atx | |
| AR093801A1 (es) | Derivados de 1,4-ditiina sustituida y su uso como fungicidas | |
| CO2024001256A2 (es) | Compuesto inductor de la degradación de plk1 novedoso |